letrozole

P2, N=178, Active, not recruiting, Dartmouth-Hitchcock Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Apr 2025

P3, N=4800, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2026 --> Jan 2025

This case highlights that cutaneous autoimmune-like toxicities, while concerning in appearance, do not necessarily warrant discontinuation of an effective anticancer drug if they are mild.Oncologists and dermatologists should be aware of CDK4/6 inhibitor-associated vitiligo, even late in the treatment timeline, and approach it with a collaborative management strategy.Moving forward, further research into the immunological or apoptotic mechanisms of this toxicity may shed light on why it occurs and how best to treat it.

P3, N=123, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | N=2032 --> 123 | Trial completion date: Mar 2032 --> Oct 2030

P3, N=300, Not yet recruiting, Rovi Pharmaceuticals Laboratories

P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24

This study provides the first human evidence with long-term ET administration to reveal that, besides genetic profiles, the gut microbiota is another critical factor that we should consider in the influence and prediction of breast cancer recurrence in the future.

No 3-year breast cancer-specific survival events are observed in these patients. These data provide a rationale for CT-sparing trials in this setting.

Background/Objectives: Aromatase inhibitors (AIs)-specifically, letrozole, anastrozole and exemestane-represent the current gold standard for patients with estrogen-receptor-positive breast cancer (ER + BC). The data presented herein are derived from in vitro, in silico, and animal model studies and await validation in large patient cohorts. Nevertheless, these findings pave the way for future research to elucidate these molecular phenomena in humans and to establish clinically significant conclusions for ER + BC patients.

Ribociclib in combination with letrozole showed clear antitumor efficacy and safe treatment option in older patients with advanced breast cancer regardless of frailty. Frequent dose reductions and early discontinuation suggest the need for more research to optimize dosing in older patients.

Targeted therapies of lapatinib, fulvestrant, and endocrine agents (letrozole or ribociclib) show disproportionately high AE reporting odds ratios, necessitating vigilant monitoring. HER2-positive BC treatments (trastuzumab) and TNBC agents (sonidegib) exhibit distinct risk profiles, advocating for personalized risk-benefit assessments for BC patients.